{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-024648","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.233560+00:00","generated_at":"2026-06-02T21:27:01.168068+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ionis Q1 revenue $119M, loss $150M; WAINUA launch delivers $1M royalty; olezarsen NDA filed for FCS","bullets":["Q1 total revenue $119M, down 9% YoY from $131M; GAAP operating loss $150M vs $114M prior year.","SPINRAZA royalties $38M (down from $50M); WAINUA contributed $1M royalty in first partial quarter of launch.","Cash and short-term investments $2.2B; 2024 financial guidance reaffirmed.","Olezarsen NDA submitted to FDA for FCS; positive Phase 3 donidalorsen data for HAE, preparing regulatory submissions.","Pipeline progress: eplontersen fast track for ATTR cardiomyopathy, bepirovirsen fast track for CHB, ION224 positive Phase 2 for MASH."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-024648","json":"https://secwatch.observer/filing/0001140361-24-024648.json","markdown":"https://secwatch.observer/filing/0001140361-24-024648.md","text":"https://secwatch.observer/filing/0001140361-24-024648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036124024648/0001140361-24-024648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036124024648/ef20028585_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:27:01.168068+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b70d27270826127e2391a979cf4b58c19053def5","claim":"IONIS PHARMACEUTICALS INC updated its first quarter ended March 31, 2024 guidance (reaffirmed).","evidence_excerpt":"On May 7, 2024, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036124024648/0001140361-24-024648-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}